FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma

FDA approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.

Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news